 Brigitte Frohnert
Concepts (278)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 45 | 2025 | 3625 | 3.500 |
Why?
| | Islets of Langerhans | 19 | 2024 | 790 | 2.640 |
Why?
| | Autoimmunity | 21 | 2023 | 860 | 2.220 |
Why?
| | Autoantibodies | 29 | 2025 | 1461 | 1.680 |
Why?
| | Celiac Disease | 5 | 2022 | 286 | 0.930 |
Why?
| | Genetic Predisposition to Disease | 11 | 2023 | 2261 | 0.920 |
Why?
| | Protein Carbonylation | 3 | 2015 | 55 | 0.890 |
Why?
| | Insulins | 1 | 2023 | 37 | 0.800 |
Why?
| | Insulin Resistance | 6 | 2013 | 1164 | 0.770 |
Why?
| | Oxidative Stress | 3 | 2013 | 1181 | 0.770 |
Why?
| | Insulin Infusion Systems | 3 | 2023 | 362 | 0.660 |
Why?
| | Child, Preschool | 27 | 2023 | 10378 | 0.660 |
Why?
| | Adipocytes | 4 | 2013 | 205 | 0.660 |
Why?
| | Child | 40 | 2025 | 20636 | 0.610 |
Why?
| | Bone Density | 3 | 2020 | 474 | 0.580 |
Why?
| | Insulin | 9 | 2023 | 2316 | 0.580 |
Why?
| | HLA-D Antigens | 1 | 2017 | 34 | 0.560 |
Why?
| | Infusions, Subcutaneous | 1 | 2015 | 20 | 0.500 |
Why?
| | Disease Progression | 10 | 2024 | 2598 | 0.480 |
Why?
| | Fatty Acids, Nonesterified | 2 | 2013 | 159 | 0.480 |
Why?
| | Infant | 18 | 2023 | 8912 | 0.480 |
Why?
| | Equipment Failure | 1 | 2015 | 107 | 0.480 |
Why?
| | Prospective Studies | 14 | 2023 | 7035 | 0.460 |
Why?
| | Models, Genetic | 1 | 2017 | 591 | 0.460 |
Why?
| | Blood Glucose Self-Monitoring | 4 | 2025 | 601 | 0.450 |
Why?
| | Adolescent | 26 | 2025 | 20158 | 0.440 |
Why?
| | Genotype | 7 | 2022 | 1828 | 0.430 |
Why?
| | Hypoglycemic Agents | 4 | 2023 | 1212 | 0.420 |
Why?
| | Blood Glucose | 4 | 2025 | 2092 | 0.420 |
Why?
| | Lipid Peroxidation | 1 | 2013 | 147 | 0.400 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2020 | 2059 | 0.400 |
Why?
| | Humans | 60 | 2025 | 128020 | 0.390 |
Why?
| | DNA Methylation | 3 | 2023 | 604 | 0.380 |
Why?
| | Adiposity | 3 | 2013 | 504 | 0.380 |
Why?
| | Subcutaneous Fat, Abdominal | 1 | 2011 | 13 | 0.370 |
Why?
| | Biomarkers | 5 | 2023 | 3874 | 0.370 |
Why?
| | Fasting | 2 | 2010 | 264 | 0.350 |
Why?
| | Case-Control Studies | 10 | 2023 | 3324 | 0.350 |
Why?
| | Metabolomics | 1 | 2015 | 599 | 0.340 |
Why?
| | Obesity | 3 | 2013 | 2859 | 0.340 |
Why?
| | Male | 35 | 2025 | 62758 | 0.320 |
Why?
| | Female | 36 | 2025 | 68017 | 0.310 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2019 | 45 | 0.300 |
Why?
| | Cystic Fibrosis | 3 | 2012 | 1048 | 0.270 |
Why?
| | Mitochondria | 1 | 2013 | 847 | 0.270 |
Why?
| | Inflammation | 2 | 2017 | 2646 | 0.270 |
Why?
| | Macrophages | 1 | 2013 | 1460 | 0.250 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 851 | 0.230 |
Why?
| | Oxylipins | 2 | 2023 | 31 | 0.230 |
Why?
| | HLA-DR4 Antigen | 3 | 2021 | 78 | 0.220 |
Why?
| | Cardiovascular Diseases | 2 | 2013 | 1994 | 0.220 |
Why?
| | HLA-DR3 Antigen | 3 | 2021 | 80 | 0.220 |
Why?
| | Membrane Transport Proteins | 3 | 1999 | 148 | 0.220 |
Why?
| | Carrier Proteins | 4 | 2000 | 730 | 0.210 |
Why?
| | GTP-Binding Proteins | 2 | 2021 | 155 | 0.200 |
Why?
| | Technology | 1 | 2023 | 84 | 0.200 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2015 | 2428 | 0.200 |
Why?
| | Transglutaminases | 2 | 2021 | 153 | 0.200 |
Why?
| | HLA-DR Antigens | 3 | 2022 | 224 | 0.200 |
Why?
| | Risk Factors | 11 | 2025 | 9696 | 0.200 |
Why?
| | Glutathione Transferase | 2 | 2013 | 99 | 0.200 |
Why?
| | Growth Charts | 1 | 2022 | 14 | 0.190 |
Why?
| | Glucose Tolerance Test | 3 | 2018 | 356 | 0.190 |
Why?
| | Longitudinal Studies | 5 | 2022 | 2706 | 0.190 |
Why?
| | Body Height | 1 | 2022 | 192 | 0.180 |
Why?
| | Diet, Ketogenic | 1 | 2021 | 35 | 0.180 |
Why?
| | Diet, Carbohydrate-Restricted | 1 | 2021 | 32 | 0.180 |
Why?
| | Prediabetic State | 1 | 2023 | 245 | 0.170 |
Why?
| | Glutamate Decarboxylase | 4 | 2022 | 166 | 0.170 |
Why?
| | Young Adult | 7 | 2025 | 12282 | 0.170 |
Why?
| | Mannose | 1 | 2019 | 25 | 0.170 |
Why?
| | Adenosine Diphosphate | 1 | 2019 | 78 | 0.160 |
Why?
| | Inservice Training | 1 | 2020 | 111 | 0.160 |
Why?
| | Glucose Intolerance | 2 | 2010 | 142 | 0.160 |
Why?
| | Butyrates | 1 | 2019 | 54 | 0.160 |
Why?
| | Ascorbic Acid | 1 | 2019 | 119 | 0.160 |
Why?
| | Osteoporotic Fractures | 1 | 2020 | 57 | 0.160 |
Why?
| | Fibrinogen | 1 | 2019 | 158 | 0.150 |
Why?
| | Insulin-Secreting Cells | 1 | 2023 | 367 | 0.150 |
Why?
| | Membrane Proteins | 3 | 1999 | 1105 | 0.150 |
Why?
| | Fatty Acids | 3 | 2000 | 415 | 0.150 |
Why?
| | Mentors | 1 | 2020 | 178 | 0.150 |
Why?
| | Cross-Sectional Studies | 5 | 2020 | 5034 | 0.150 |
Why?
| | Mass Spectrometry | 1 | 2021 | 662 | 0.150 |
Why?
| | Thiazolidinediones | 1 | 1999 | 137 | 0.150 |
Why?
| | Mammals | 1 | 2000 | 268 | 0.150 |
Why?
| | Interprofessional Relations | 1 | 2020 | 270 | 0.140 |
Why?
| | Cohort Studies | 5 | 2022 | 5378 | 0.140 |
Why?
| | Mentoring | 1 | 2020 | 130 | 0.140 |
Why?
| | Discriminant Analysis | 1 | 2017 | 38 | 0.140 |
Why?
| | Triglycerides | 1 | 2000 | 523 | 0.140 |
Why?
| | Absorptiometry, Photon | 2 | 2020 | 248 | 0.140 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 1999 | 215 | 0.140 |
Why?
| | Health Care Costs | 1 | 2020 | 366 | 0.140 |
Why?
| | Osteoporosis | 1 | 2020 | 233 | 0.140 |
Why?
| | Models, Statistical | 1 | 2021 | 621 | 0.130 |
Why?
| | Infant, Newborn | 5 | 2022 | 5688 | 0.130 |
Why?
| | Polymorphism, Genetic | 1 | 2019 | 638 | 0.130 |
Why?
| | History, 21st Century | 1 | 2017 | 177 | 0.130 |
Why?
| | Family Health | 1 | 2017 | 194 | 0.130 |
Why?
| | HLA-DQ Antigens | 1 | 2017 | 179 | 0.130 |
Why?
| | Organelle Biogenesis | 1 | 2015 | 14 | 0.130 |
Why?
| | Mass Screening | 2 | 2021 | 1145 | 0.120 |
Why?
| | Disease-Free Survival | 1 | 2017 | 647 | 0.120 |
Why?
| | Proteins | 1 | 2021 | 933 | 0.120 |
Why?
| | Subcutaneous Fat | 1 | 2015 | 74 | 0.120 |
Why?
| | Age of Onset | 1 | 2017 | 490 | 0.120 |
Why?
| | Guidelines as Topic | 1 | 2017 | 260 | 0.120 |
Why?
| | Hypoglycemia | 1 | 2020 | 425 | 0.120 |
Why?
| | Genetic Testing | 1 | 2018 | 428 | 0.120 |
Why?
| | Proteomics | 1 | 2021 | 1008 | 0.120 |
Why?
| | Intestinal Mucosa | 1 | 2000 | 575 | 0.120 |
Why?
| | DNA-Binding Proteins | 2 | 2015 | 1421 | 0.110 |
Why?
| | Gastric Bypass | 1 | 2015 | 107 | 0.110 |
Why?
| | Body Mass Index | 2 | 2013 | 2260 | 0.110 |
Why?
| | Aldehyde Reductase | 1 | 2013 | 27 | 0.110 |
Why?
| | Transcription Factors | 2 | 2015 | 1628 | 0.110 |
Why?
| | Autoimmune Diseases | 1 | 2017 | 423 | 0.100 |
Why?
| | Age Factors | 3 | 2020 | 3100 | 0.100 |
Why?
| | Growth Disorders | 1 | 2013 | 80 | 0.100 |
Why?
| | Muscle Cells | 1 | 2013 | 39 | 0.100 |
Why?
| | Ultrasonography, Doppler | 1 | 2013 | 118 | 0.100 |
Why?
| | Aldehydes | 1 | 2013 | 138 | 0.100 |
Why?
| | Models, Biological | 1 | 2019 | 1689 | 0.100 |
Why?
| | Human Growth Hormone | 1 | 2012 | 45 | 0.100 |
Why?
| | Glutathione | 1 | 2013 | 340 | 0.090 |
Why?
| | Aldehyde Dehydrogenase, Mitochondrial | 1 | 2011 | 23 | 0.090 |
Why?
| | Consensus | 2 | 2024 | 607 | 0.090 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2011 | 27 | 0.090 |
Why?
| | Intra-Abdominal Fat | 1 | 2011 | 88 | 0.090 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2011 | 100 | 0.090 |
Why?
| | United States | 4 | 2022 | 13785 | 0.080 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2011 | 281 | 0.080 |
Why?
| | Adult | 6 | 2025 | 35177 | 0.080 |
Why?
| | Sensitivity and Specificity | 3 | 2022 | 1813 | 0.080 |
Why?
| | Diabetic Ketoacidosis | 2 | 2024 | 197 | 0.080 |
Why?
| | Time Factors | 2 | 2017 | 6479 | 0.080 |
Why?
| | Survivors | 1 | 2012 | 462 | 0.080 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1185 | 0.070 |
Why?
| | Glucose | 1 | 2013 | 983 | 0.070 |
Why?
| | RNA, Messenger | 2 | 2015 | 2669 | 0.070 |
Why?
| | Predictive Value of Tests | 3 | 2019 | 1934 | 0.070 |
Why?
| | Obesity, Morbid | 1 | 2011 | 239 | 0.070 |
Why?
| | Hyperglycemia | 1 | 2010 | 326 | 0.070 |
Why?
| | Genetic Association Studies | 2 | 2020 | 361 | 0.070 |
Why?
| | Overweight | 1 | 2011 | 522 | 0.070 |
Why?
| | Colorado | 3 | 2023 | 4369 | 0.060 |
Why?
| | Follow-Up Studies | 3 | 2021 | 4853 | 0.060 |
Why?
| | Risk Assessment | 3 | 2020 | 3223 | 0.060 |
Why?
| | Fatty Acid Transport Proteins | 3 | 1999 | 18 | 0.060 |
Why?
| | Diabetes Mellitus | 1 | 2012 | 994 | 0.050 |
Why?
| | GTPase-Activating Proteins | 1 | 2023 | 81 | 0.050 |
Why?
| | CpG Islands | 1 | 2023 | 151 | 0.050 |
Why?
| | Prognosis | 3 | 2018 | 3766 | 0.050 |
Why?
| | Finland | 1 | 2022 | 90 | 0.050 |
Why?
| | Germany | 1 | 2022 | 97 | 0.050 |
Why?
| | Seroepidemiologic Studies | 1 | 2023 | 155 | 0.050 |
Why?
| | Mice | 3 | 2013 | 16574 | 0.050 |
Why?
| | Diagnostic Techniques, Radioisotope | 1 | 2021 | 9 | 0.050 |
Why?
| | Linoleic Acid | 1 | 2021 | 41 | 0.050 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 1 | 2021 | 62 | 0.040 |
Why?
| | Animals | 5 | 2013 | 34487 | 0.040 |
Why?
| | Perception | 1 | 2023 | 336 | 0.040 |
Why?
| | Immunoglobulin D | 1 | 2021 | 29 | 0.040 |
Why?
| | Arachidonic Acid | 1 | 2021 | 114 | 0.040 |
Why?
| | Serologic Tests | 1 | 2021 | 50 | 0.040 |
Why?
| | Markov Chains | 1 | 2021 | 116 | 0.040 |
Why?
| | Iodide Peroxidase | 1 | 2020 | 28 | 0.040 |
Why?
| | Docosahexaenoic Acids | 1 | 2021 | 83 | 0.040 |
Why?
| | Electrochemical Techniques | 1 | 2021 | 48 | 0.040 |
Why?
| | Benchmarking | 1 | 2022 | 175 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2021 | 83 | 0.040 |
Why?
| | Glutens | 1 | 2020 | 57 | 0.040 |
Why?
| | Coenzyme A Ligases | 1 | 1999 | 13 | 0.040 |
Why?
| | Absorption | 1 | 2000 | 57 | 0.040 |
Why?
| | Transfection | 2 | 1999 | 891 | 0.040 |
Why?
| | Whole Genome Sequencing | 1 | 2020 | 130 | 0.040 |
Why?
| | Peroxidase | 1 | 2020 | 169 | 0.040 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 106 | 0.040 |
Why?
| | Femur Neck | 1 | 2020 | 59 | 0.040 |
Why?
| | Diffusion | 1 | 2000 | 118 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2023 | 569 | 0.040 |
Why?
| | Clinical Protocols | 1 | 2021 | 253 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2021 | 272 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2021 | 200 | 0.040 |
Why?
| | Physicians, Women | 1 | 2020 | 70 | 0.040 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2021 | 488 | 0.040 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 200 | 0.040 |
Why?
| | Chromans | 1 | 1999 | 23 | 0.040 |
Why?
| | Immunoglobulin E | 1 | 2021 | 329 | 0.040 |
Why?
| | Retinoid X Receptors | 1 | 1999 | 40 | 0.040 |
Why?
| | Oleic Acid | 1 | 1999 | 39 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2020 | 234 | 0.040 |
Why?
| | Receptors, Retinoic Acid | 1 | 1999 | 51 | 0.040 |
Why?
| | 3T3 Cells | 1 | 1999 | 151 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2023 | 601 | 0.040 |
Why?
| | Gene Frequency | 1 | 2020 | 504 | 0.040 |
Why?
| | Biological Transport | 1 | 2000 | 396 | 0.040 |
Why?
| | Dimerization | 1 | 1999 | 188 | 0.040 |
Why?
| | Tandem Mass Spectrometry | 1 | 2021 | 452 | 0.040 |
Why?
| | Thiazoles | 1 | 1999 | 115 | 0.040 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 1998 | 87 | 0.040 |
Why?
| | Peer Group | 1 | 2020 | 224 | 0.040 |
Why?
| | Nutritional Status | 1 | 2021 | 326 | 0.040 |
Why?
| | Base Sequence | 2 | 1999 | 2134 | 0.040 |
Why?
| | Minority Groups | 1 | 2020 | 250 | 0.040 |
Why?
| | Interleukins | 1 | 2020 | 240 | 0.040 |
Why?
| | Career Choice | 1 | 2020 | 207 | 0.040 |
Why?
| | Tretinoin | 1 | 1999 | 127 | 0.040 |
Why?
| | Lumbar Vertebrae | 1 | 2020 | 230 | 0.040 |
Why?
| | Postmenopause | 1 | 2020 | 348 | 0.040 |
Why?
| | Neoplasms | 1 | 2012 | 2460 | 0.040 |
Why?
| | ROC Curve | 1 | 2019 | 500 | 0.040 |
Why?
| | Quantitative Trait Loci | 1 | 2020 | 355 | 0.040 |
Why?
| | Universities | 1 | 2020 | 399 | 0.040 |
Why?
| | Social Media | 1 | 2020 | 137 | 0.040 |
Why?
| | Collagen | 1 | 2020 | 429 | 0.040 |
Why?
| | Molecular Sequence Data | 2 | 1999 | 2820 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 567 | 0.030 |
Why?
| | Gestational Age | 1 | 2020 | 868 | 0.030 |
Why?
| | Pelvic Bones | 1 | 2020 | 155 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 419 | 0.030 |
Why?
| | Occupational Exposure | 1 | 2020 | 299 | 0.030 |
Why?
| | Anxiety | 1 | 2023 | 951 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2021 | 842 | 0.030 |
Why?
| | Societies, Medical | 1 | 2020 | 741 | 0.030 |
Why?
| | Social Support | 1 | 2020 | 588 | 0.030 |
Why?
| | Nuclear Respiratory Factor 1 | 1 | 2015 | 3 | 0.030 |
Why?
| | Prevalence | 1 | 2023 | 2541 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2021 | 733 | 0.030 |
Why?
| | Up-Regulation | 1 | 1999 | 822 | 0.030 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2015 | 41 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2023 | 1482 | 0.030 |
Why?
| | Electron Transport Complex IV | 1 | 2015 | 57 | 0.030 |
Why?
| | Insulin Antibodies | 1 | 2016 | 105 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2018 | 396 | 0.030 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 337 | 0.030 |
Why?
| | Coronavirus Infections | 1 | 2020 | 333 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 614 | 0.030 |
Why?
| | Risk | 1 | 2018 | 850 | 0.030 |
Why?
| | Parents | 1 | 2023 | 1303 | 0.030 |
Why?
| | Nitric Oxide Synthase | 1 | 2015 | 230 | 0.030 |
Why?
| | Chronic Disease | 1 | 2021 | 1690 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 1194 | 0.030 |
Why?
| | Sex Factors | 1 | 2020 | 1942 | 0.030 |
Why?
| | Family | 1 | 2018 | 648 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3009 | 0.030 |
Why?
| | Mitochondrial Proteins | 1 | 2015 | 245 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1492 | 0.020 |
Why?
| | DNA | 1 | 1999 | 1392 | 0.020 |
Why?
| | Glucose Clamp Technique | 1 | 2012 | 194 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1473 | 0.020 |
Why?
| | Physicians | 1 | 2020 | 858 | 0.020 |
Why?
| | Cell Differentiation | 1 | 1999 | 1896 | 0.020 |
Why?
| | Middle Aged | 3 | 2020 | 30813 | 0.020 |
Why?
| | Haplotypes | 1 | 2012 | 471 | 0.020 |
Why?
| | Minnesota | 1 | 2010 | 148 | 0.020 |
Why?
| | Incidence | 1 | 2017 | 2614 | 0.020 |
Why?
| | Cytokines | 1 | 2017 | 1984 | 0.020 |
Why?
| | Fatty Liver | 1 | 2009 | 231 | 0.020 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2009 | 163 | 0.020 |
Why?
| | Metabolic Syndrome | 1 | 2009 | 338 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2009 | 541 | 0.020 |
Why?
| | Aged | 1 | 2020 | 21892 | 0.010 |
Why?
| | Sequence Analysis | 1 | 1999 | 37 | 0.010 |
Why?
| | COS Cells | 1 | 1999 | 184 | 0.010 |
Why?
| | Introns | 1 | 1998 | 249 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 1998 | 522 | 0.010 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 1998 | 313 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 1998 | 504 | 0.010 |
Why?
| | Exons | 1 | 1998 | 338 | 0.010 |
Why?
| | Alternative Splicing | 1 | 1998 | 216 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 1998 | 771 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 1998 | 1198 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2010 | 14404 | 0.010 |
Why?
| | Protein Binding | 1 | 1998 | 2105 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 1998 | 1403 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 1998 | 2508 | 0.000 |
Why?
|
|
Frohnert's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|